VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Not diagnosed with Type 2 diabetes                 │ Not diagnosed with Type 2 diabetes                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Meet at least 3 of 5 National Cholesterol          │ Meet at least 3 of 5 National Cholesterol          │     100 │
│ Education Adult Treatment Panel III                │ Education Adult Treatment Panel III                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of type 1 diabetes and diabetics          │ Evidence of type 1 diabetes and diabetics          │     100 │
│ requiring insulin therapy                          │ requiring insulin therapy                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects prescribed metformin or have taken        │ Subjects prescribed metformin or have taken        │     100 │
│ metformin within 1 year                            │ metformin within 1 year                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with abnormal estimated glomerular        │ Subjects with abnormal estimated glomerular        │     100 │
│ filtration rate (eGFR)                             │ filtration rate (eGFR)                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects currently taking medications that affect  │ Subjects currently taking medications that affect  │     100 │
│ heart rate and rhythm (i.e. Ca++ channel blockers, │ heart rate and rhythm (i.e. Ca++ channel blockers, │         │
│ nitrates, alpha- or beta-blockers)                 │ nitrates, alpha- or beta-blockers)                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with a history of significant metabolic,  │ Subjects with a history of significant metabolic,  │     100 │
│ cardiac, congestive heart failure,                 │ cardiac, congestive heart failure,                 │         │
│ cerebrovascular, hematological, pulmonary,         │ cerebrovascular, hematological, pulmonary,         │         │
│ gastrointestinal, liver, renal, or endocrine       │ gastrointestinal, liver, renal, or endocrine       │         │
│ disease or cancer that in the investigator's       │ disease or cancer that in the investigator's       │         │
│ opinion would interfere with or alter the outcome  │ opinion would interfere with or alter the outcome  │         │
│ measures, or impact subject safety                 │ measures, or impact subject safety                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant (as evidenced by positive pregnancy test) │ Pregnant (as evidenced by positive pregnancy test) │     100 │
│ or nursing women                                   │ or nursing women                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects with contraindications to participation   │ Subjects with contraindications to participation   │     100 │
│ in an exercise training program                    │ in an exercise training program                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Currently taking active weight suppression         │ Currently taking active weight suppression         │     100 │
│ medication (e.g. phentermine,orlistat, lorcaserin, │ medication (e.g. phentermine,orlistat, lorcaserin, │         │
│ naltrexone-bupropion in combination, liraglutide,  │ naltrexone-bupropion in combination, liraglutide,  │         │
│ benzephetamine, diethylpropion, phendimetrazine)   │ benzephetamine, diethylpropion, phendimetrazine)   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known hypersensitivity to perflutren (contained in │ Known hypersensitivity to perflutren (contained in │     100 │
│ Definity)                                          │ Definity)                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male or female \>40 and \<70 years old             │ Male or female >40 and <70 years old               │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Increased waist circumference (≥102 cm in men; ≥88 │ Increased waist circumference (=102 cm in men; =88 │      97 │
│ cm in women)                                       │ cm in women)                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Has a body mass index \>27 and \<47 kg/m2          │ Has a body mass index >27 and <47 kg/m2            │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ High blood pressure (≥130 mmHg systolic or ≥85mmHg │ High blood pressure (=130 mmHg systolic or =85mmHg │      98 │
│ diastolic), or on medication for treating the      │ diastolic), or on medication for treating the      │         │
│ condition                                          │ condition                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hypertensive (\>160/100 mmHg)                      │ Hypertensive (>160/100 mmHg)                       │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Not currently engaged in \> 60 min/wk of exercise  │ Not currently engaged in > 60 min/wk of exercise   │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Elevated triglycerides (≥150 mg/dl), or on         │ Elevated triglycerides (=150 mg/dl), or on         │      99 │
│ medication for treating the condition              │ medication for treating the condition              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Reduced HDL-cholesterol (\<40mg/dl in men, \<50    │ Reduced HDL-cholesterol (<40mg/dl in men, <50      │      99 │
│ mg/dl in women), or on medication for treating the │ mg/dl in women), or on medication for treating the │         │
│ condition                                          │ condition                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Elevated fasting glucose (≥100 mg/dl), or on       │ Elevated fasting glucose (=100 mg/dl), or on       │      99 │
│ medication for treating the condition              │ medication for treating the condition              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Morbidly obese patients (BMI \>47 kg/m2) and       │ Morbidly obese patients (BMI >47 kg/m2) and        │      99 │
│ overweight/lean patients (BMI \<27 kg/m2)          │ overweight/lean patients (BMI <27 kg/m2)           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who have not been weight stable (\>2 kg   │ Subjects who have not been weight stable (>2 kg    │      99 │
│ weight change in past 3 months)                    │ weight change in past 3 months)                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who have been recently active (\>30 min   │ Subjects who have been recently active (>30 min of │      99 │
│ of moderate/high intensity exercise, 2 times/week) │ moderate/high intensity exercise, 2 times/week)    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who are smokers or who have quit smoking  │ Subjects who are smokers or who have quit smoking  │      99 │
│ \<5 years ago                                      │ <5 years ago                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hypertriglyceridemic (\>400 mg/dl) and             │ Hypertriglyceridemic (>400 mg/dl) and              │      99 │
│ hypercholesterolemic (\>260 mg/dl) subjects        │ hypercholesterolemic (>260 mg/dl) subjects         │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                               │   Score │
╞═══════════════════════════════════╪═════════════════════════════════════════════╪═════════╡
│ Metabolic Syndrome criteria       │ Subjects with abnormal estimated glomerular │      37 │
│                                   │ filtration rate (eGFR)                      │         │
├───────────────────────────────────┼─────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 40 Years │ Male or female >40 and <70 years old        │      43 │
├───────────────────────────────────┼─────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 70 Years │ Male or female >40 and <70 years old        │      46 │
╘═══════════════════════════════════╧═════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 93.03571428571429
OverAll Ratio: 95.01785714285714
